臨床泌尿器科78巻5号

2024年04月発行

特集 人生100年時代の老年泌尿器科診療

〈各論―悪性腫瘍〉

人生100年時代の前立腺癌診療

著者： 星誠二¹ 八木沼恵¹ 小島祥敬¹

所属機関： ¹福島県立医科大学 泌尿器科学講座

ページ範囲：P.298 - P.305

文献概要

▶ポイント

・前立腺癌患者の治療は年齢だけでは決定できない．

・高齢者の身体・社会機能にはグラデーションがあり評価が必要である．

・高齢前立腺癌の治療には十分なエビデンスの確立が求められる．

参考文献

1） Kotwal AA, et al : Cancer Screening Among Older Adults : a Geriatrician's Perspective on Breast, Cervical, Colon, Prostate, and Lung Cancer Screening. Curr Oncol Rep 22 : 108, 2020

2） Bill-Axelson A, et al : Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364 : 1708-1717, 2011

3） Scosyrev E, et al : Prostate cancer in the elderly : frequency of advanced disease at presentation and disease-specific mortality. Cancer 118 : 3062-3070, 2012

4） Ko YH, et al : A comparison of the survival outcomes of robotic-assisted radical prostatectomy and radiation therapy in patients over 75 years old with non-metastatic prostate cancer : A Korean multicenter study. Investig Clin Urol 62 : 535-544, 2021

5） Jin K, et al : How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer? Cancer Med 8 : 3370-3378, 2019

6） Leyh-Bannurah SR, et al : Feasibility of robot-assisted radical prostatectomy in men at senior age ≥ 75 years : perioperative, functional, and oncological outcomes of a high-volume center. Aging Male 25 : 8-16, 2022

7） Labanaris AP, et al : Robotic-assisted radical prostatectomy in men ≥ 75 years of age. Surgical, oncological and functional outcomes. Anticancer Res 32 : 2085-2089, 2012

8） Yamada Y, et al : Comparison of perioperative outcomes in elderly （age ≧ 75 years） vs. younger men undergoing robot-assisted radical prostatectomy. PloS One 15 : e0234113, 2020

9） Togashi K, et al : Oncologic and patient-reported outcomes after robot-assisted radical prostatectomy in men aged ≥ 75 years. Urol Oncol 39 : 729.e17-729.e25, 2021

10） Wu SY, et al : Acute, Subchronic, and Chronic Complications of Radical Prostatectomy Versus Radiotherapy With Hormone Therapy in Older Adults With High-Risk Prostate Adenocarcinoma. Front Oncol 12 : 875036, 2022

11） Nam RK, et al : Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer : a population-based cohort study. Lancet Oncol 15 : 223-231, 2014

12） Rosiello G, et al : Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical prostatectomy. Prostate Cancer Prostatic Dis 23 : 573-580, 2020

13） Bill-Axelson A, et al : Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl J Med 379 : 2319-2329, 2018

14） Vernooij RW, et al : Radical prostatectomy versus deferred treatment for localised prostate cancer. Cochrane Database Syst Rev 6 : Cd006590, 2020

15） 日本泌尿器科学会 （編） : 前立腺癌診療ガイドライン2023年版. メディカルレビュー社, 2023

16） Fizazi K, et al : Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 377 : 352-360, 2017

17） Matsuoka T, et al : Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer. J Cancer Res Clin Oncol 141 : 759-765, 2015

18） Narita S, et al : Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer : historically controlled, propensity score matched comparison with androgen deprivation therapy. World J Urol 40 : 1135-1141, 2022

19） Sweeney CJ, et al : Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 373 : 737-746, 2015

20） Davis ID, et al : Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med 381 : 121-131, 2019

21） Chi KN, et al : Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 381 : 13-24, 2019

22） Chi KN, et al : Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer : Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J Clin Oncol 39 : 2294-2303, 2021

23） Afferi L, et al : Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors : the role of combination treatment therapy. Prostate Cancer Prostatic Dis 2023 ［Online ahead of print］

24） Hanson ED, et al : Body composition, physical function and quality of life in healthy men and across different stages of prostate cancer. Prostate Cancer Prostatic Dis 24 : 725-732, 2021

25） Briggs LG, et al : Neurocognitive impairment associated with traditional and novel androgen receptor signaling inhibitors ± androgen deprivation therapy : a pharmacovigilance study. Prostate Cancer Prostatic Dis 26 : 331-337, 2023

26） De Nunzio C, et al : Adverse events related to abiraterone and enzalutamide treatment : analysis of the EudraVigilance database and meta-analysis of registrational phase III studies. Prostate Cancer Prostatic Dis 23 : 199-206, 2020

27） Lu-Yao G, et al : Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities. Eur Urol 77 : 158-166, 2020

28） Niraula S, et al : Treatment of prostate cancer with intermittent versus continuous androgen deprivation : a systematic review of randomized trials. J Clin Oncol 31 : 2029-2036, 2013

29） Zhang X, et al : The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer : A network meta-analysis. Front Endocrinol （Lausanne） 14 : 1131033, 2023

30） Izumi K, et al : Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer : A Multicenter Randomized Controlled Trial. Eur Urol Open Sci 41 : 16-23, 2022

31） Alibhai SMH, et al : Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer. Cancer 127 : 2587-2594, 2021